Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05YTG
|
|||
| Former ID |
DNCL001850
|
|||
| Drug Name |
SLx-4090
|
|||
| Synonyms |
SLx 4090; SCHEMBL1484252
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y] | Phase 2 | [1] | |
| Dyslipidemia [ICD-11: 5C80-5C81] | Phase 2 | [1] | ||
| Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.4, E78.5] | Phase 2 | [1] | ||
| Company |
Surface
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H25F3N2O4
|
|||
| Canonical SMILES |
COC1=CC=CC(=C1C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=CC4=C(CN(CC4)C(=O)OC5=CC=CC=C5)C=C3
|
|||
| InChI |
1S/C31H25F3N2O4/c1-39-27-9-5-8-26(28(27)20-10-13-23(14-11-20)31(32,33)34)29(37)35-24-15-12-22-19-36(17-16-21(22)18-24)30(38)40-25-6-3-2-4-7-25/h2-15,18H,16-17,19H2,1H3,(H,35,37)
|
|||
| InChIKey |
AZUIUVJESCFSLJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 913541-47-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Microsomal triglyceride transfer protein (MTTP) | Target Info | Modulator | [2] |
| KEGG Pathway | Fat digestion and absorption | |||
| Reactome | Chylomicron-mediated lipid transport | |||
| WikiPathways | Statin Pathway | |||
| Lipid digestion, mobilization, and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01675154) Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia. U.S. National Institutes of Health. | |||
| REF 2 | A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.